课题基金 / 基金详情

DF/HCC Prostate SPORE

DF/HCC Prostate SPORE
DF/HCC 前列腺孢子
批准号:
10628270
负责人:
Steven P. Balk
金额:
$258.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2028-08-31
关键词:
AccelerationAcuteAddressAndrogen ReceptorAutopsyBackBasic ScienceBiologicalBiological AssayBiological MarkersBiometryBloodBlood specimenCancer BiologyCancer CenterCancer EtiologyCaringCessation of lifeClinicalClinical InvestigatorClinical ResearchClinical SciencesClinical TrialsCollaborationsCommunicationCommunitiesComputational BiologyDana-Farber Cancer InstituteDataDedicationsDevelopmentDiagnosisDiseaseDisease ResistanceEZH2 geneEarly DiagnosisEarly treatmentEnsureEnvironmentEpigenetic ProcessFosteringFundingGeneral HospitalsGenomicsGoalsGrowthHospitalsIndividualInfrastructureInstitutionIsraelLaboratoriesLaboratory ResearchLeadMachine LearningMalignant NeoplasmsMalignant neoplasm of prostateMassachusettsMedical centerMentorsMolecularMorbidity - disease rateNeoadjuvant TherapyNewly DiagnosedPathologyPathway interactionsPatient advocacyPatientsPhenotypePopulation SciencesPre-Clinical ModelPrincipal InvestigatorPrognostic MarkerProstateProstate Cancer therapyRecruitment ActivityResearchResearch PersonnelResistanceResistance developmentResourcesServicesSpecimenTherapeuticTissuesTranslatingTranslational ResearchTranslationsUnited StatesWorkWritinganticancer researchbench to bedsidebiomarker developmentbiomarker discoverybiomarker drivencancer genomicscancer initiationcareercastration resistant prostate cancerclinical translationcohortcombatdata sharingdeep learningdrug standardepigenomefollow-uphigh riskimprovedindividualized medicineinnovationinsightmeetingsmenmodel developmentmortalitynext generationnext generation sequencingnovelnovel strategiespatient populationpre-clinicalprecision medicineprecision oncologypreclinical studyprogramsprostate cancer riskrepositoryresistance mechanismsuccesstherapy resistanttranslational approachtranslational cancer researchtranslational scientisttumortumor progression

项目摘要

项目成果

Steven P. Balk的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY – OVERALL The Dana-Farber/Harvard Cancer Center (DF/HCC) Prostate SPORE seeks to improve the understanding and treatment of prostate cancer using a highly translational approach. The application consists of three Projects, three Cores, a Developmental Research Program and a Career Enhancement Program. The SPORE infrastructure will facilitate interactions and collaboration within our thriving community of basic, clinical, and population science researchers dedicated to prostate cancer research. Each project addresses a fundamental challenge that contributes to prostate cancer morbidity and mortality. Project 1 leverages tumor specimens from patients with high-risk prostate cancer treated with neoadjuvant therapies to understand how tumors respond and resist acute potent androgen receptor blockade and to develop novel strategies to improve cure rates and combat resistance. Project 2 will develop innovative strategies to target the epigenome in later stages of advanced castration resistant prostate cancer and will develop a first-in-field clinical trial focused on co-targeting EZH2 and PARP. Project 3 delves deep into biomarkers in localized prostate cancer, leveraging innovations in computation and biologically-guided deep learning, to deliver on precision cancer medicine in this disease state. The ability to understand why some localized prostate cancers are phenotypically aggressive and predict which localized prostate cancers will behave in this manner addresses a large clinical unmet need. Each of these projects combines elegant preclinical work with innovative clinical studies led by DF/HCC investigators. Core A, the Administrative Core, will be the center for scientific, fiscal and administrative oversight. It will lead efforts in planning and communication, and also house the Patient Advocacy Committee. Core A will ensure that the DF/HCC infrastructure supports the SPORE clinical and translational research efforts. Core B, the Biostatistics and Computational Biology core, will provide specialized expertise in biostatistics and the management of genomic and other next generation sequencing data and data sharing. Core C, the Biospecimen and Pathology Core, will maintain tissue/blood repositories for the SPORE projects as well as other investigators within the prostate cancer program. It will provide critical expertise and pathology services including next generation molecular assays and will help facilitate the use of fresh tumor specimens including rapid autopsies for patient derived model development to accelerate translational investigation. The Developmental Research and Career Enhancement Programs will identify and fund innovative projects that address basic, translational, and clinical research questions and unmet needs in prostate cancer and will support early career and new prostate cancer investigators. These programs will actively recruit and retain researchers from diverse backgrounds to foster cutting-edge and impactful prostate cancer translational science. We anticipate that the DF/HCC Prostate SPORE will make substantial scientific discoveries in the field and translate directly into benefits for men with prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer
Enhancing the Efficacy of Docetaxel in Prostate Cancer
Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs
Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs
海外基金